Top

Clinical Rheumatology

Published in:

01-02-2022 | Ankylosing Spondylitis | Original Article

Real-world effectiveness and rheumatologist satisfaction with secukinumab in the treatment of patients with axial spondyloarthritis

Authors: U. Kiltz, D. L. Keininger, E. A. Holdsworth, N. Booth, O. Howell, N. Modi, H. Tian, P. G. Conaghan

Published in: Clinical Rheumatology | Issue 2/2022

Abstract

Objectives

To assess the effectiveness of secukinumab in patients with axSpA treated in routine clinical settings in 5 European countries.

Methods

Retrospective analysis of a cross-sectional survey to assess real-world effectiveness of secukinumab in the management of axSpA and rheumatologist satisfaction with treatment in France, Germany, Italy, Spain and the UK from March to December 2018. Outcomes collected included patient demographics, clinical characteristics and rheumatologist- and patient-reported satisfaction with secukinumab treatment.

Results

Five hundred thirty-five patients receiving secukinumab for more than 4 months were assessed, 359 of whom were diagnosed with AS and 178 with nr-axSpA. Rheumatologist assessment of disease status at treatment initiation indicated that 39 (7.3%) had stable/improving disease. Secukinumab treatment for 4 months or longer resulted in 515 (95.9%) patients judged as stable/improving. Treatment was associated with benefits from initiation to assessment in terms of BASDAI (6.2 vs 2.8), 44-joint count score (9.7 vs 6.6), rheumatologist global VAS score (56.9 vs 23.0) and patient global VAS scores (64.4 vs 25.5). These benefits for key clinical outcomes were sustained for periods of 12 months or longer. Patient-reported outcomes on health status using EQ-5D, global functioning using the ASAS health index and overall work impairment via WPAI were sustained over the treatment period, while patient and rheumatologist satisfaction with secukinumab treatment remained very high at 80.2 and 91.2%, respectively.

Conclusion

Consistent benefits across multiple clinical and patient-reported outcomes were seen with secukinumab treatment in patients with AS and nr-axSpA treated in routine clinical settings across five European countries.

Key Points

• In routine clinical settings across five European countries, secukinumab treatment resulted in improvements in a wide range of clinical outcomes including physician-reported disease severity, disease status, pain, BASDAI, 44-joint count score and global VAS scores.

• Key clinical and patient reported outcomes were sustained for a 12-month period or longer with secukinumab treatment.

• Rheumatologist- and patient-reported treatment satisfaction was high with secukinumab.

Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet (London, England) 390(10089):73–84. https://doi.org/10.1016/s0140-6736(16)31591-4CrossRef

Sieper J, Braun J, Dougados M, Baeten D (2015) Axial spondyloarthritis. Nature reviews Disease primers 1:15013. https://doi.org/10.1038/nrdp.2015.13

Rudwaleit M, Khan MA, Sieper J (2005) The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 52(4):1000–1008. https://doi.org/10.1002/art.20990CrossRefPubMed

Mease PJ, Heijde DV, Karki C, Palmer JB, Liu M, Pandurengan R, Park Y, Greenberg JD (2018) Characterization of patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis in the US-Based Corrona Registry. Arthritis Care Res 70(11):1661–1670. https://doi.org/10.1002/acr.23534CrossRef

Deodhar A, Mease PJ, Reveille JD, Curtis JR, Chen S, Malhotra K, Pangan AL (2016) Frequency of axial spondyloarthritis diagnosis among patients seen by US rheumatologists for evaluation of chronic back pain. Arthritis & rheumatology (Hoboken, NJ) 68(7):1669–1676. https://doi.org/10.1002/art.39612CrossRef

Poddubnyy D (2013) Axial spondyloarthritis: is there a treatment of choice? Therapeutic advances in musculoskeletal disease 5(1):45-54. https://doi.org/10.1177/1759720X12468658

van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compàn V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978–991. https://doi.org/10.1136/annrheumdis-2016-210770CrossRefPubMed

Davis JC, Jr., Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study G (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48(11):3230–3236. https://doi.org/10.1002/art.11325CrossRef

van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study G (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582–591. https://doi.org/10.1002/art.20852CrossRef

10.

van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, Dijkmans BA, Mease PJ, Davis JC, Jr., Group AS (2009) Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Annals of the rheumatic diseases 68 (6):922-929. https://doi.org/10.1136/ard.2007.087270

11.

Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L (2019) 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis & rheumatology (Hoboken, NJ) 71(10):1599–1613. https://doi.org/10.1002/art.41042CrossRef

12.

Brahe CH, Ørnbjerg LM, Askling J, Ciurea A, Kristianslund EK, Onen F, Nordström D, Santos MJ CC, Rotar Z, Gudbjornsson B, Di Giuseppe D, Nissen MJ, Kvien T, Birlik M, Trokovic N, Barcelos A, Ionescu R, Tomšič M, Geirsson AJ, Loft AG, Mann HF, Rusman T, Gomez-Reino JJ, Jones GT, Iannone F, Pavelka K, van der Horst-Bruinsma I, Hyldstrup L, Krogh NS, Hetland ML, Østergaard M. (2018) Drug retention and response rates of TNFi treatment in 21,470 patients with axial spondyloarthritis treated in clinical practice– pooled data from the Eurospa Research Network Collaboration. Arthritis & rheumatology (Hoboken, NJ) 70 (suppl 10).

13.

McGonagle DG, McInnes IB, Kirkham BW, Sherlock J, Moots R (2019) The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis 78(9):1167–1178. https://doi.org/10.1136/annrheumdis-2019-215356CrossRefPubMed

14.

Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, Group MS, Group MS (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373(26):2534–2548. https://doi.org/10.1056/NEJMoa1505066CrossRef

15.

Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, Readie A, Martin R, Mpofu S, Richards HB, group Ms, (2017) Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 76(6):1070–1077. https://doi.org/10.1136/annrheumdis-2016-209730CrossRefPubMed

16.

Deodhar A, Conaghan PG, Kvien TK, Strand V, Sherif B, Porter B, Jugl SM, Gandhi KK, group Ms, (2019) Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study. Clin Exp Rheumatol 37(2):260–269PubMed

17.

Marzo-Ortega H, Sieper J, Kivitz AJ, Blanco R, Cohen M, Pavelka K, Delicha EM, Stefanska A, Richards HB, Rohrer S (2020) 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. Lancet Rheumatol 2(6):e339–e346. https://doi.org/10.1016/S2665-9913(20)30066-7CrossRef

18.

Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, Van den Bosch F, Delicha EM, Talloczy Z, Fierlinger A (2019) Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open 5(2):e001005. https://doi.org/10.1136/rmdopen-2019-001005CrossRefPubMedPubMedCentral

19.

Braun J, Blanco R, Dokoupilova E, Gensler LS, Kivitz A, Hall S, Kameda H, Poddubnyy D, Van de Sande M, Van der Heijde D, Wiksten A, Porter B, Richards H, Haemmerle S, Deodhar A (2020) OP0106 Secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: 52-week results from the phase iii PREVENT study. Ann Rheum Dis 79(1):69–70. https://doi.org/10.1136/annrheumdis-2020-eular.598CrossRef

20.

Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T (2019) Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther 21(1):111. https://doi.org/10.1186/s13075-019-1882-2CrossRefPubMedPubMedCentral

21.

Anderson P, Benford M, Harris N, Karavali M, Piercy J (2008) Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand. Curr Med Res Opin 24(11):3063–3072. https://doi.org/10.1185/03007990802457040CrossRefPubMed

22.

Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291PubMed

23.

van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LB (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Annals of the rheumatic diseases 49 (11):916-920. https://doi.org/10.1136/ard.49.11.916

24.

Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35(11):1095–1108. https://doi.org/10.1097/00005650-199711000-00002CrossRefPubMed

25.

EuroQol G (1990) EuroQol–a new facility for the measurement of health-related quality of life. Health Policy 16(3):199–208. https://doi.org/10.1016/0168-8510(90)90421-9CrossRef

26.

Kiltz U, van der Heijde D, Boonen A, Cieza A, Stucki G, Khan MA, Maksymowych WP, Marzo-Ortega H, Reveille J, Stebbings S, Bostan C, Braun J (2015) Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis 74(5):830–835. https://doi.org/10.1136/annrheumdis-2013-203967CrossRefPubMed

27.

Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5):353–365. https://doi.org/10.2165/00019053-199304050-00006CrossRefPubMed

28.

Public Policy Committee ISoP (2016) Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf 25(1):2–10. https://doi.org/10.1002/pds.3891CrossRef

29.

Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M, initiative S, (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 147(8):W163-194. https://doi.org/10.7326/0003-4819-147-8-200710160-00010-w1CrossRefPubMed

30.

Ariza-Ariza R, Hernandez-Cruz B, Lopez-Antequera G, Navarro-Sarabia F (2009) Variables related to utility in patients with ankylosing spondylitis. Clin Rheumatol 28(2):207–211. https://doi.org/10.1007/s10067-008-1019-5CrossRefPubMed

31.

Elolemy G, Aboughanima A, Ganeb S, Elziat H (2020) Health-related quality of life in patients with ankylosing spondylitis: relationship with disease-related variables. Curr Rheumatol Rev 16(4):311–318. https://doi.org/10.2174/1573397115666191018162606CrossRefPubMed

32.

Kiltz U, Peterlik D, Winkelmann V, Tony H-P (2019) FRI0406 AQUILA study in Germany - Real world data on secukinumab’s effectiveness in ankylosing spondylitis patients - results from an interim analysis. Ann Rheum Dis 78(Suppl 2):890–890. https://doi.org/10.1136/annrheumdis-2019-eular.437CrossRef

33.

Michelsen B, Brahe CH, Askling J, Codreanu C, Ciurea A, Loft AG, Mann H, Pombo-Suarez M, Onen F, Sexton J, Rotar Z, Santos MJ, Eklund K, Gudbjornsson B, Iannone F, Giuseppe DD, Ionescu R, Nissen M, Pavelka K, Sánchez-Piedra C, Akar S, Kristianslund E, Tomsic M, Santos H, Trokovic N, Geirsson AJ, Favalli EG, Ivd H-B, Macfarlane G, Hyldstrup L, Krogh NS, Ǿstergaard M, Hetland ML (2019) FRI0404 Pooled 6-month treatment outcomes and drug retention rates in 1556 patients with axial spondyloarthritis treated with secukinumab in routine clinical practice in 12 European countries in the EUROSPA research collaboration. Ann Rheum Dis 78(Suppl 2):888–889. https://doi.org/10.1136/annrheumdis-2019-eular.1601CrossRef

34.

Chen Q, Beal EW, Okunrintemi V, Cerier E, Paredes A, Sun S, Olsen G, Pawlik TM (2019) The association between patient satisfaction and patient-reported health outcomes. J Patient Exp 6(3):201–209. https://doi.org/10.1177/2374373518795414CrossRefPubMed

35.

Kaye DR, Richardson CR, Ye Z, Herrel LA, Ellimoottil C, Miller DC (2017) Association between patient satisfaction and short-term outcomes after major cancer surgery. Ann Surg Oncol 24(12):3486–3493. https://doi.org/10.1245/s10434-017-6049-2CrossRefPubMedPubMedCentral

36.

Derakhshan MH, Pathak H, Cook D, Dickinson S, Siebert S, Gaffney K, Nass, investigators BR, (2018) Services for spondyloarthritis: a survey of patients and rheumatologists. Rheumatology (Oxford) 57(6):987–996. https://doi.org/10.1093/rheumatology/kex518CrossRef

37.

Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, Chirila C, Park Y (2019) A pilot study to assess the feasibility of a web-based survey to examine patient-reported symptoms and satisfaction in patients with ankylosing spondylitis receiving secukinumab. Drugs Real World Outcomes 6(2):83–91. https://doi.org/10.1007/s40801-019-0154-4CrossRefPubMedPubMedCentral

38.

Gonzalez CM, Carmona L, de Toro J, Batlle-Gualda E, Torralba AI, Arteaga MJ, Cea-Calvo L (2017) Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products. Patient Prefer Adherence 11:1243–1252. https://doi.org/10.2147/PPA.S137052CrossRefPubMedPubMedCentral

Title: Real-world effectiveness and rheumatologist satisfaction with secukinumab in the treatment of patients with axial spondyloarthritis
Authors: U. Kiltz
D. L. Keininger
E. A. Holdsworth
N. Booth
O. Howell
N. Modi
H. Tian
P. G. Conaghan
Publication date: 01-02-2022
Publisher: Springer International Publishing
Keywords: Ankylosing Spondylitis
Spondyloarthropathy
Secukinumab
Published in: Clinical Rheumatology / Issue 2/2022
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-021-05957-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2022

Body mass index trend and variability in rheumatoid arthritis

Serum level of fetuin-A in systemic lupus erythematosus patients: association with atherosclerosis and disease activity

ANCA-associated vasculitis in Caucasian and Hispanics of the Inland Empire of Southern California

Association of interleukin-6 promoter polymorphism with rheumatoid arthritis: a meta-analysis with trial sequential analysis

Differentiation of idiopathic pulmonary hemosiderosis from rheumatologic and autoimmune diseases causing diffuse alveolar hemorrhage: establishing a diagnostic approach

Factors affecting quality of life in patients with rheumatoid arthritis in South Korea: a cross-sectional study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials